GlassScriptPhysician profile
John T Bailey
NPI 1437115813
$1,661.73
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $287 · 2021: $480 · 2022: $349 · 2024: $27.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $471.78 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $257.47 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.44 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $87.57 | 2019-2022 | |
| Neuronetics, INC. | $86.18 | 2019 | |
| Abbvie INC. | $82.43 | 2021-2022 | |
| Lundbeck LLC | $72.84 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $66.42 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $60.80 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.92 | 2020-2021 | |
| Allergan, INC. | $58.49 | 2019 | |
| Novo Nordisk INC | $44.47 | 2020-2022 | |
| Alkermes, INC. | $40.95 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2024 | Cobenfy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $26.30 | 2019 | |
| Adlon Therapeutics L.P. | $19.96 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.19 | 2021 | |
| Eisai INC. | $15.49 | 2020 | |
| Alfasigma USA, INC. | $13.09 | 2021 | |
| Bausch Health US, LLC | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.